The Hospital Is Moving Into Your Living Room

NHS virtual wards hit record capacity in 2026 as telehealth platforms like Doccla scale hospital-at-home models across the European continent

2 Mar 2026

For years, the idea of treating hospital patients at home sounded more like a thought experiment than a health policy. In January 2026, it became a milestone. NHS virtual wards in England recorded their highest-ever occupancy levels, according to NHS England Digital, a sign that telehealth-enabled home care is no longer a post-pandemic workaround. It has become part of the architecture.

The mechanics are well-established by now. Patients admitted to virtual wards wear devices that continuously transmit vital signs including blood pressure, oxygen saturation, and heart rate to clinical monitoring hubs. Algorithms flag risk. Nurses intervene in real time. NHS England's national target is occupancy consistently above 80% across virtual ward capacity, and recent data shows the system hitting that mark across cardiology, respiratory, frailty, and cancer recovery pathways simultaneously.

Driving much of the continental expansion is Doccla, whose virtual ward platform now operates across 11 European countries. After a £35 million Series B in September 2024, the company has been active in France and the DACH region, replicating the clinical infrastructure it first built with the NHS. Its UK data is compelling: a 63% reduction in A&E attendance among enrolled patients, and a reported return of £3 for every £1 invested. For health systems wrestling with workforce shortages and strained bed capacity, those numbers tend to accelerate procurement.

The structural foundation is also solidifying. In February 2026, the NHS launched a standardised patient-level minimum dataset for virtual wards, approved by the NHS Data Assurance Board. Standardised data is the prerequisite for interoperability and, eventually, for integration with the European Health Data Space framework that entered force in March 2025. Operators with cross-border footprints can now take clinical evidence generated in one market and translate it directly into procurement arguments in another. The evaluation phase is over. What's happening now is scale.